These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30498279)

  • 1. Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer.
    Müller V; Wöckel A; Lux MP; Janni W; Hartkopf AD; Nabieva N; Taran FA; Hadji P; Tesch H; Ettl J; Lüftner D; Welslau M; Belleville E; Brucker SY; Schütz F; Fasching PA; Fehm TN; Kolberg HC; Schneeweiss A; Overkamp F
    Geburtshilfe Frauenheilkd; 2018 Nov; 78(11):1119-1128. PubMed ID: 30498279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer.
    Nabieva N; Fasching PA
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.
    Wöckel A; Lux MP; Janni W; Hartkopf AD; Nabieva N; Taran FA; Overkamp F; Hadji P; Tesch H; Ettl J; Lüftner D; Müller V; Welslau M; Belleville E; Brucker SY; Schütz F; Fasching PA; Fehm TN; Schneeweiss A; Kolberg HC
    Geburtshilfe Frauenheilkd; 2018 Nov; 78(11):1110-1118. PubMed ID: 30498278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
    D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D
    Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
    Nur Husna SM; Tan HT; Mohamud R; Dyhl-Polk A; Wong KK
    Ther Adv Med Oncol; 2018; 10():1758835918808509. PubMed ID: 30542378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.
    Habler K; Kalla AS; Rychlik M; Vogeser M; Teupser D
    J Pharm Biomed Anal; 2023 Feb; 225():115211. PubMed ID: 36603395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
    Iuliani M; Simonetti S; Ribelli G; Napolitano A; Longo UG; Vincenzi B; Orsaria P; Denaro V; Tonini G; Santini D; Francesco P
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
    Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
    J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer.
    Zhao S; Zhang H; Yang N; Yang J
    Transl Cancer Res; 2023 Jun; 12(6):1617-1634. PubMed ID: 37434680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.